Shots:

• BMS reported 3.5yrs. data from EXPLORER-LTE cohort of 5yrs. P-III (MAVA-LTE) trial of Camzyos to treat symptomatic oHCM patients who concluded P-III (EXPLORER-HCM; n=251) trial
• 211/231 were on Camyos (185 & 99 reached wk.156 & 180, respectively). Analysis showed a 55.3 mmHg reduced Valsalva LVOT gradient (both wks.156 & 180) with 40.2 mmHg (wk.156) & 40.3 mmHg (wk.180) reduced mean resting LVOT gradient; mean LVEF decreased by 11% (wk.180); median NT-proBNP levels dropped by 504 ng/L (wk.156) & 562 ng/L (wk.180)
• Reductions in mean left atrial volume index were 3.5 mL/m² (wks.144) & 5.5 mL/m² (wks.180). CR was observed in 46.8% of patients at wk.180 (66.3% were NYHA class I), with sustained improvement in shortness of breath at wks.156 & 180

Ref: BMS | Image: BMS

Related News:- BMS’ Camzyos (mavacamten) Receives NICE Recommendation for adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com